烟台益诺依生物医药科技

Yinuoyi Biotech is a clinical-stage biopharmaceutical company headquartered in Yantai, China, specializing in the development of small molecule drugs for metabolic disorders. The company's research focuses on high-impact targets such as the thyroid hormone receptor beta (THR-β) and the glucagon-like peptide 1 receptor (GLP-1R). Its lead candidate, YN-001, is a highly selective THR-β agonist designed to treat non-alcoholic steatohepatitis (NASH) by improving lipid metabolism while minimizing systemic side effects. Additionally, the company is advancing a pipeline of oral small molecule GLP-1R agonists for obesity and type 2 diabetes. Yinuoyi leverages its medicinal chemistry expertise to create differentiated therapies that address significant unmet needs in the metabolic space. The company is led by a team of industry veterans with extensive experience in global drug discovery and development.